| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Record revenue of $12.3 million, increased 22% year over year |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Four success pillars driving higher revenue growth and operating leverage |
| 26 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Myomo, Inc., a corporation organized and existing under virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”) does hereby certify as follows: |
| 13 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BURLINGTON, MA. (May 13, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysi... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources |
| 16 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BURLINGTON, MA. (April 16, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paraly... |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million |
| 16 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 10, 2025, the Compensation Committee of the Board of Directors of Myomo, Inc. (the “Company”) approved a salary-for-restricted stock units (“RSUs”) program open to all salaried employees pursuant to which (i) Paul Gudonis, th... |
| 10 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
(in such capacity, together with each other lender from time to time party hereto, a “Lender” and collectively, the “Lenders”) |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
BURLINGTON, Mass. (August 11, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb par... |
| 18 Jun 2025 |
8-K: Regulation FD Disclosure
Senior executives to provide an in-depth review of the Company’s business model and discuss long-range aspirational financial metrics |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Myomo, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2025. As of April 14, 2025, the record date for the Annual Meeting, there were 35,978,651 shares of the Company’s common stock outstan... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training |
| 10 Apr 2025 |
8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation +1 more
BURLINGTON, Mass. (April 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb para... |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
Generated first-ever positive quarterly cash flow from operations |
| 20 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation
This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 18th day of February, 2025 by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and MYOMO, INC., a Dela... |
| 05 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
3,000,000 Shares of Common Stock, par value $0.0001 per share |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end |
| 13 Aug 2024 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1.1. |
| 06 Aug 2024 |
8-K: Results of Operations and Financial Condition
Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end |
Loading...